Curcumin liposomal - Signpath Pharma

Drug Profile

Curcumin liposomal - Signpath Pharma

Alternative Names: Diferuloylmethane; Lipocurc; Lipocurcumin; Liposomal curcumin

Latest Information Update: 18 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Signpath Pharma
  • Class Anti-ischaemics; Antihistamines; Antivirals; Catechols; Chemopreventatives; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action NF-kappa B inhibitors; Proto oncogene protein c-akt inhibitors; Toll-like receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 18 Jul 2016 Development for Solid tumours is ongoing
  • 09 Apr 2015 Signpath Pharma has patent protection for curcumin liposomal in USA (Signpath Pharma form 10-K, April 2015)
  • 26 Sep 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top